Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making
ConclusionsThe model simulations were used to derive dosing recommendations for co-administering entrectinib with CYP3A4 inhibitors or inducers. PBPK modeling has been used in lieu of clinical studies to enable regulatory decision-making.
Source: European Journal of Drug Metabolism and Pharmacokinetics - Category: Drugs & Pharmacology Source Type: research
More News: Biaxin | Cancer & Oncology | Carbamazepine | Clarithromycin | Diltiazem | Drugs & Pharmacology | Erythromycin | Fluconazole | Phenytoin | Study | Verapamil